U.S. Army Botulinum Neurotoxin (BoNT) medical therapeutics research program: Past accomplishments and future directions

Drug Development Research

Volumn 70, Issue 4, 2009, Pages 266-278

  Larsen, Joseph C ^a  

^a DEFENSE THREAT REDUCTION AGENCY   (United States)

Author keywords

Botulinum; Department of defense; Therapeutics

Indexed keywords

BOTULINUM TOXIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

AFFINITY CHROMATOGRAPHY; BIOLOGICAL WARFARE; BIOSAFETY; BOTULISM; DRUG EFFICACY; DRUG PROGRAM; DRUG RESEARCH; FLUORESCENCE RESONANCE ENERGY TRANSFER; NONHUMAN; NOTE;

EID: 67649316049     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20304     Document Type: Note

References (73)

1. Adler M, Scovill J, Parker G, Lebeda FJ, Piotrowski J, Deshpande SS. 1995. Antagonism of botulinum toxin-induced muscle weakness by 3, 4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon 33:527-537.
2. Adler M, MacDonald DA, Sellin LC, Parker GW. 1996. Effect of 3, 4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neuorotoxin. Toxicon 34:237-249. (Pubitemid 26067896)
3. Adler M, Dinterman RE, Wannemacher RW 1997. Protection by the heavy metal chelator N, N, N′, N′-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 35:1089-1100. (Pubitemid 27304195)
4. Adler M, Nicholson JD, Starks DF, Kane CT, Cornille F, Hackley BE. 1999. Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity. J Appl Toxicol 1:S5-S11. (Pubitemid 30093512)
5. Adler M, Capacio B, Deshpande SS. 2000. Antagonism of botulism A-mediated muscle paralysis by 3, 4-diaminopyridine delivered by osmotic minipumps. Toxicon 38:1381-1388. (Pubitemid 30176108)
6. Adler M, Keller JE, Sheridan RE, Deshpande SS. 2001. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 39:233-243.
7. Adler M, Apland JP, Hilmas C, Ternay A, Janda K, Deshpande SS. 2006. Meeting Abstract 43rd Interagency Botulism Research Coordinating Committee Meeting. Nov 14-17, 2006 Silver Spring, Maryland.
8. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. 1997. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 65:3743-3752. (Pubitemid 27398135)
9. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. 2002. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20:1640-1648. (Pubitemid 34169806)
10. Apland JP, Biser JA, Adler M, Ferrer-Montiel AV, Montal M, Canaves JM, Filbert MG. 1999. Peptides that mimic the carboxy-terminal domain of SNAP-25 block acetylcholine release at an Aplysia synapse. J Appl Toxicol 19:23-26. (Pubitemid 30093515)
11. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. 2006. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 362:733-742. (Pubitemid 44404084)
12. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen, E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. 2001. For the Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
13. Black RE, Gunn RA. 1980. Hypersensitivity reaction associated with botulinal antitoxin. JAMA 69:567-570. (Pubitemid 10018712)
14. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, Stafford RG, Lane DJ, Kenny TA, McGrath CF, Wipf P, Stahl AM, Schmidt JJ, Gussio R, Brunger AT, Bavari S. 2007a. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecules that is active in primary neurons. J Biol Chem 282:5004-5014. (Pubitemid 47100957)
15. Burnett JC, Opsenica D, Sriraghavan K, Panchal RG, Ruthel G, Hermone AR, Nguyen TL, Kenny TA, Lane DJ, McGrath CF, Schmidt JJ, Vennerstrom JL, Gussio R, Solaja BA, Bavari S. 2007b. A refined pharmacophore identifies potent 4-amino-7chloroquinoline-based inhibitors of the Botulinum neurotoxin serotype A metalloprotease. J Med Chem 50:2127-2136. (Pubitemid 46683065)
16. Centers for Disease Control and Prevention. 1998. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, Georgia. 42p.
17. Chen S, Barbieri JT. 2007. Multi-pocket recognition of SNAP25 by botulinum neurotoxinserotype E. J Biol Chem 282:25540-25547. (Pubitemid 47372783)
18. Chen S, Kim JJ, Barbieri JT. 2007. Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem 282:9621-9627.
19. Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresntiz EA, Weisman RS, Berstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR. 2006. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated Botulinum preparation. JAMA 296:2476-2479. (Pubitemid 44791204)
20. Colcher D, Milenic DE, Ferroni P, Carrasquillo JA, Reynolds JC, Roselli M, Larson SM, Schlom J. 1990. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 31:1133-1142.
21. DasGupta BR, Sugiyama H. 1972. A common subunit structure in Clostridium botulinum type A, B, and E toxins. Biochem Biophys Res Commun 1:108-112.
22. Deshpande SS, Sheridan RE, Adler M. 1995. A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 33:551-557.
23. Deshpande SS, Sheridan RE, Adler M. 1997. Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 35:433-435. (Pubitemid 27102263)
24. Ding J, Xu TH, Shi YL. 2001. Different effects of toosendanin on perineurially recorded Ca(2+) currents in mouse and frog motor nerve terminals. J Neurosci Res 41:243-249. (Pubitemid 32982891)
25. Dong M, Tepp WH, Johnson EA, Chapman ER. 2004. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. PNAS 101:14701-14706. (Pubitemid 39410738)
26. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006a. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596.
27. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006b. The binding and entry of BoNT/A and B into neurons require both their specific protein receptors and gangliosides. Abstract 43rd Interagency Botulism Research Coordinating Committee Meeting, Nov 14-17 2006 Silver Spring, MD.
28. Encinar JA, Fernandez A, Ferragut JA, Gonzalez-Ros JM, DasGupta BR, Montal M, Ferrer-Montiel A. 1998. Structural stabilization of botulinum neurotoxins by tyrosine phosphorylation. FEBS Lett 429:78-82. (Pubitemid 28281249)
29. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, Johnson EA, Boger DL, Dickerson TJ, Janda KD. 2007. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA 104:2602-2607. (Pubitemid 46327926)
30. Ferrer-Montiel AV, Oblatt-Montal M, Canaves J, Gutierrez LM, Nelson R, Yamazaki M, Montal M. 1996. Botulinum neurotoxins: design of peptide inhibitors of neurosecretion and identification of the ion-channel forming module. Abstract 1996 USAMRMC Medical Defense Bioscience Review May 12-16, 1996.
31. Franz D, Pitt L, Clayton M, Hanes M, Rose K. 1993. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalational botulism. In: DasGupta BR, editor. Botulism and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press. p 473-476.
32. Garcia GE, Moorad DR, Gordon RK. 1999. Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro. J Appl Toxicol 1:S19-S22. (Pubitemid 30093514)
33. Goodnough MC, Oyler G, Fishman PS, Johnson EA, Neale EA, Keller JE, Tepp WH, Clark M, Hartz S, Adler M. 2002. Development of a delivery vehicle for intracellular transport of Botulinum neurotoxin antagonists. FEBS Lett 513:163-168. (Pubitemid 34251257)
34. Hack DC. 1993. Clinical safety and pharamacokinetics of botulinum immune globulin (human). AIBS Peer Review to USAMRMC. Medical Biological Defense Research Program on Botulinum Toxin. Feb 22, 1993.
35. Hatheway CL. 1990. Toxigenic clostridia. Clin Microbiol Rev 3:66-98. (Pubitemid 20078775)
36. Hererro BA, Ecklung AE, Streett CS, Ford DF, King JK. 1967. Experimental botulism in monkeys: a clinical pathological study. Exp Mol Pathol 6:84-95.
37. Hibbs RG, Weber JT, Corwin A, Allos BM, Abdel Rehim MS, Sharkawy SE, Sarn JE, MckEE Jr KT. 1996. Experience with the use of an investigational F(ab′)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 23:337-340. (Pubitemid 26264919)
38. Holzer VE. 1962. Botulism from inhalation. (Translated from German) Med Klin 57:1735-1738.
39. Keller JE, Neale EA, Oyler G, Adler M. 1999a. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142. (Pubitemid 29339056)
40. Keller JE, Nowakowski JL, Filbert MG, Adler M. 1999b. Rapid microplate assay for monitoring botulinum neurotoxin B catalytic activity. J Appl Toxicol 19:S13-S17. (Pubitemid 30093513)
41. Koriazova LK, Montal M. 2003. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10:13-18. (Pubitemid 36034171)
42. Lebeda FJ. 2004. BotBD: A database resource for clostridial neurotoxins. Mov Disord 19:35-41. (Pubitemid 38967509)
43. Lebeda FJ, Olson MA. 1995. Structural predictions of the channel-forming region of botulinum neurotoxin heavy chain. Toxicon 33:559-567.
44. Lebeda FJ, Olson MA. 1998. Predictions of secondary structure and solvent accessibility of the light chain of the clostridial neurotoxins. J Nat Toxins 7:227-238. (Pubitemid 28456459)
45. Lewis GE, Metzger JF. 1978. Botulism immune plasma. Lancet 2:634-635.
46. Lewis GE, Metzger JF. 1980. Studies on the prophylaxis and treatment of botulism. In: Eaker D, Wadstrom T, editors. Natural Toxins. Oxford: Pergamon Press. p 601-606.
47. Merino I, Thompson JD, Millard CB, Schmidt JJ, Pang Y-P. 2006. Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem 14:3583-3591.
48. Middlebrook J, Fraz D. 2004. Botulism toxins. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare: Office of the Surgeon General, Borden Institute. Washington, DC: Walter Reed Army Medical Center. p 643-654.
49. Millard C. 2006. Medical defense against toxin weapons: review and perspective. In: Lindler LE, Lebeda FJ, Korch GW, editors. Infectious disease: biological weapons defense: infectious diseases and counterterrorism. Totowa, NJ: Humana Press Inc. p 255-276.
50. Montecucco C. 1986. How do tetanus and botulinum toxin bind to neuronal cell membranes? Trends Biochem Sci 11:314-317.
51. Montecucco C, Rossetto O, Schiavo G. 2004. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol 10:442-446. (Pubitemid 39286121)
52. Nath J, Powledge A, Wright DG. 1994. Involvement of a botulinum toxin-sensitive 22-kDa G protein in stimulated exocytosis of human neutrophils. J Immunol 152:1370-1379. (Pubitemid 24134366)
53. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 99:11346-11350. (Pubitemid 34920928)
54. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, Schmidt JJ, Pang Y-P. 2006. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum serotype A. Bioorg Med Chem 14:395-408. (Pubitemid 41767599)
55. Poulain B, Mochida S, Weller U, Hogy B, Habermann E, Wadsworth JD, Shone CC, Dolly JO, Tauc L. 1991. Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia. J Biol Chem 266:9580-9585. (Pubitemid 21906695)
56. Ray P, Berman JD, Middleton W, Brendle J. 1993. Botulinum toxin inhibits arachidonic acid release associated with acetylcholine release from PC12 cells. J Biol Chem 268:11057-11064. (Pubitemid 23162292)
57. Ray P, Ishida H, Millard CB, Petrali JP, Ray R. 1999. Phospholipase A2 and arachidonic acid-mediated mechanism of neuroexocytosis: a possible target of botulinum neurotoxin A other then SNAP-25. J Appl Toxicol S1:27-28. (Pubitemid 30093516)
58. Rizo J. 2003. SNARE function revisited. Nat Struct Biol 10:417-419. (Pubitemid 36637636)
59. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Bigalke H, Binz T. 2007. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. PNAS 104:359-364. (Pubitemid 46068036)
60. Schmidt JJ, Stafford RG. 2002. A high-affinity competitive inhibitor of type A Botulinum neurotoxin protease activity. FEBS Lett 532:423-426. (Pubitemid 35441386)
61. Schmidt JJ, Stafford RG, Millard CB. 2001. High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal Biochem 296:130-137. (Pubitemid 32808404)
62. Scott AB, Suzuki D. 1988. Systemic toxicity of botulism toxin by intramuscular injection in the monkey. Mov Disord 3:333-335.
63. Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 129:221-228. (Pubitemid 28377513)
64. Sharma SK, Singh BR. 1998. Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis. J Nat Toxin 7:239-253. (Pubitemid 28456460)
65. Sheridan RE. 1996. Protonophore antagonism of botulinum toxin in mouse muscle. Toxicon 34:849-855. (Pubitemid 26273995)
66. Sheridan RE, Deshpande SS. 1995. Interactions between heavy metal chelators and botulinum neurotoxins at the mouse neuromuscular junction. Toxicon 33:539-549.
67. Sheridan RE, Deshpande SS, Smith T. 1999. Comparison of in vivo and in vitro mouse bioassays for botulinum toxin antagonists. J Appl Toxicol 19:S29-S33. (Pubitemid 30093517)
68. Shih YL. 1986. Abolishment of non-quantal release of acetylcholine from the mouse phrenic nerve terminals by toosendanin. Jpn J Physiol 36:601-605. (Pubitemid 17198014)
69. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, Janda KD, Allen KN. 2007. Structures of Clostridium botulinum neurotoxin serotype a light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol 14:533-542. (Pubitemid 46765150)
70. Smart JK. 1997. History of chemical and biological warfare: an American perspective. In: Medical Aspects of Chemical and Biological Warfare. Textbook of Military Medicine: Office of the Surgeon General, Borden Institute, Washington, DC: Walter Reed Army Medical Center. p 9-86.
71. Stahl AM, Ruthel G, Torres-Melendez E, Kenny TA, Panchal RG, Bavari S. 2007. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J Biomol Screen 12:370-377. (Pubitemid 46514672)
72. Terranova W, Palumbo JN, Breman JG. 1979. Ocular findings in botulism type B. JAMA 241:475-477. (Pubitemid 9228138)
73. United Nations Security Council. 1995. Tenth Report of the executive chairman of the special established by the secretary general pursuant to paragraph 9b of security council resolution 687 (1991), and paragraph 3 of resolution 699 (1991) on the activities of the special commission. New York, NY: United Nations Security Council.